Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers grew its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 0.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 365,701 shares of the biotechnology company’s stock after purchasing an additional 2,577 shares during the quarter. Rhumbline Advisers owned approximately 0.23% of Ironwood Pharmaceuticals worth $2,384,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. PNC Financial Services Group Inc. increased its stake in Ironwood Pharmaceuticals by 152.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,645 shares during the last quarter. CWM LLC grew its holdings in Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Ironwood Pharmaceuticals by 68.8% in the fourth quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 3,497 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals in the first quarter valued at approximately $91,000. Finally, GAMMA Investing LLC increased its position in Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.52 on Thursday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $15.70. The stock’s 50-day moving average is $5.43 and its two-hundred day moving average is $6.68. The stock has a market cap of $707.51 million, a PE ratio of -0.67 and a beta of 0.49.

Analysts Set New Price Targets

IRWD has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Wells Fargo & Company reduced their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Finally, Craig Hallum decreased their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.57.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.